CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 182 enrolled
Drug / intervention
DNA methylation analysis +3 moregenetic
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00899548
NCT00899548N/ACompleted
CompareCT.gov

DNA Methylation in Serum as a Predictive Marker of Progression and Survival Following Systemic Therapy in Patients With Metastatic Breast Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·observational·Posted May 12, 2009·Updated Jul 26, 2019

In Brief

An observational study evaluating DNA methylation analysis, microarray analysis, and 2 other interventions for Breast Cancer. Completed, enrolled 182 participants across 4 sites.

Detailed Summary

RATIONALE: Studying samples of blood from patients with cancer and from healthy participants in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to systemic therapy. PURPOSE: This laboratory study is looking at DNA in predicting response after systemic therapy in women with metastatic breast cancer.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 12, 2009
Enrollment StartJan 1, 2007
Primary CompletionJun 1, 2010
Study CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 17.1 years ago

Interventions

DNA methylation analysisgenetic

laboratory analysis

microarray analysisgenetic

laboratory analysis

polymerase chain reactiongenetic

laboratory analysis

laboratory biomarker analysisother

laboratory analysis